Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio)

New Capabilities

Developer of AK0406, pursuing parallel clinical development in Australia, China, and the US

Shanghai-based ArkBio won U.S. Food and Drug Administration (FDA) clearance to test its experimental flu prevention drug in a Phase II trial. The drug, AK0406, is a long-acting antiviral designed to prevent influenza for an extended period, not just treat it after infection.

Updated Oct 13